{"id":"thimerosal","_fda":{"id":"27e6d102-3362-4318-a704-3b497f7b001a","set_id":"fdf8d21a-2ae1-4842-abf3-737841995939","openfda":{"nui":["N0000185508","N0000175629","N0000184306","M0000728"],"upc":["0810151881218"],"unii":["F79059A38U","2QNL82089R","751E8J54VM","X2N6E405GV","C62OO7VD9K","877L01IZ0P","HT3R7C012Q","YF0S03R447","2E32821G6I","FZJ641678T","U751HEX436","ETJ7Z6XBU4","2225PI3MOV","1NT28V9397"],"route":["ORAL"],"spl_id":["27e6d102-3362-4318-a704-3b497f7b001a"],"brand_name":["VAXR HC"],"spl_set_id":["fdf8d21a-2ae1-4842-abf3-737841995939"],"package_ndc":["43742-2018-1"],"product_ndc":["43742-2018"],"generic_name":["THUJA OCCIDENTALIS, MEZEREUM, SILICEA, CALCAREA CARBONICA, MORBILLINUM, PAROTIDINUM, PERTUSSINUM, RUBELLA NOSODE, TETANUS TOXIN, CARCINOSIN, ANTIMONIUM CRUDUM, LEDUM PALUSTRE, THIMEROSAL, POLIOMYELITIS NOSODE"],"product_type":["HUMAN OTC DRUG"],"pharm_class_cs":["Allergens [CS]"],"pharm_class_pe":["Increased Histamine Release [PE]","Cell-mediated Immunity [PE]"],"substance_name":["ANTIMONY TRISULFIDE","BORDETELLA PERTUSSIS","CLOSTRIDIUM TETANI","DAPHNE MEZEREUM BARK","HUMAN BREAST TUMOR CELL","LEDUM PALUSTRE TWIG","MEASLES VIRUS","MUMPS VIRUS","OYSTER SHELL CALCIUM CARBONATE, CRUDE","POLIOVIRUS","RUBELLA VIRUS","SILICON DIOXIDE","THIMEROSAL","THUJA OCCIDENTALIS LEAFY TWIG"],"pharm_class_epc":["Standardized Chemical Allergen [EPC]"],"manufacturer_name":["Deseret Biologicals, Inc."],"is_original_packager":[true]},"purpose":["PURPOSE: Antimonium Crudum - Fever, Calcarea Carbonica - Headache, Carcinosin - Rash, Ledum Palustre – Muscle Pain, Mezereum - Cough, Morbillinum - Lethargy, Parotidinum – Aching Back, Pertussinum - Fever, Poliomyelitis Nosode - Rash, Rubella Nosode – Muscle Pain, Silicea - Rash, Tetanus Toxin - Cough, Thimerosal - Lethargy, Thuja Occidentalis – Aching Back"],"version":"3","warnings":["WARNINGS: If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, contact a physician or Poison Control Center right away. Tamper Evident: Sealed for your protection. Do not use if seal is broken or missing."],"questions":["QUESTIONS: Dist. By: Deseret Biologicals, Inc. 469 W. Parkland Drive Sandy, UT 84070 www.desbio.com 800-827-8204"],"effective_time":"20240403","active_ingredient":["ACTIVE INGREDIENTS: Antimonium Crudum 30C, Calcarea Carbonica 30X, 60X, 100X, Carcinosin 15C, 30C, 50C, Ledum Palustre 30C, Mezereum 8X, 30X, Morbillinum 30X, 60X, 100X, Parotidinum 30X, 60X, 100X, Pertussinum 30X, 60X, 100X, Poliomyelitis Nosode 30C, 60C, 100C, Rubella Nosode 30X, 60X, 100X, Silicea 8X, 30X, Tetanus Toxin 30X, 60X, 100X, Thimerosal 30C, Thuja Occidentalis 6X, 30X."],"inactive_ingredient":["INACTIVE INGREDIENTS: Demineralized water, 25% ethanol"],"indications_and_usage":["USES: • For the temporary relief of symptoms including: • fever • headache • muscle pain • rash • cough • lethargy • aching back These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration."],"dosage_and_administration":["DIRECTIONS: 1-10 drops under the tongue, 3 times a day or as directed by a health professional. Consult a physician for use in children under 12 years of age."],"spl_product_data_elements":["VAXR HC Thuja Occidentalis, Mezereum, Silicea, Calcarea Carbonica, Morbillinum, Parotidinum, Pertussinum, Rubella Nosode, Tetanus Toxin, Carcinosin, Antimonium Crudum, Ledum Palustre, Thimerosal, Poliomyelitis Nosode THUJA OCCIDENTALIS LEAFY TWIG THUJA OCCIDENTALIS LEAFY TWIG DAPHNE MEZEREUM BARK DAPHNE MEZEREUM BARK SILICON DIOXIDE SILICON DIOXIDE OYSTER SHELL CALCIUM CARBONATE, CRUDE OYSTER SHELL CALCIUM CARBONATE, CRUDE MEASLES VIRUS MEASLES VIRUS MUMPS VIRUS MUMPS VIRUS BORDETELLA PERTUSSIS BORDETELLA PERTUSSIS RUBELLA VIRUS RUBELLA VIRUS CLOSTRIDIUM TETANI CLOSTRIDIUM TETANI HUMAN BREAST TUMOR CELL HUMAN BREAST TUMOR CELL ANTIMONY TRISULFIDE ANTIMONY TRISULFIDE LEDUM PALUSTRE TWIG LEDUM PALUSTRE TWIG THIMEROSAL ETHYLMERCURITHIOSALICYLIC ACID POLIOVIRUS POLIOVIRUS WATER ALCOHOL"],"keep_out_of_reach_of_children":["KEEP OUT OF REACH OF CHILDREN: In case of overdose, contact a physician or Poison Control Center right away."],"package_label_principal_display_panel":["PACKAGE LABEL DISPLAY: Des Bio VAXR:HC Homeopathic NDC 43742-2018-1 1 FL OZ (30 ml) VAXR:HC"]},"safety":{"boxedWarnings":[]},"_chembl":null,"_fixedAt":"2026-03-30T12:40:15.977292","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=THIMEROSAL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:36:50.126128+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:36:55.532101+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=THIMEROSAL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:36:55.715421+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:36:49.004817+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:36:49.004852+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:36:49.004941+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL508338/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:36:56.405192+00:00"}},"_dailymed":{"setId":"fdf8d21a-2ae1-4842-abf3-737841995939","title":"VAXR HC (THUJA OCCIDENTALIS, MEZEREUM, SILICEA, CALCAREA CARBONICA, MORBILLINUM, PAROTIDINUM, PERTUSSINUM, RUBELLA NOSODE, TETANUS TOXIN, CARCINOSIN, ANTIMONIUM CRUDUM, LEDUM PALUSTRE, THIMEROSAL, POLIOMYELITIS NOSODE) LIQUID [DESERET BIOLOGICALS, INC.]"},"mechanism":{"modality":"Small Molecule","drugClass":"Standardized Chemical Allergen [EPC]"},"_scrapedAt":"2026-03-28T00:54:09.046Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:36:58.460835+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_fixedFields":["pubmed(1356)","modality→Small Molecule"],"trialDetails":[{"nctId":"NCT06223919","phase":"PHASE3","title":"Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universidad Nacional de Colombia","startDate":"2023-12-16","conditions":"Monkeypox","enrollment":8686},{"nctId":"NCT05289375","phase":"NA","title":"Efficacy of the Vacucis Candida® Autovaccine","status":"NOT_YET_RECRUITING","sponsor":"University of Santiago de Compostela","startDate":"2025-04-30","conditions":"Oral Candidiasis, Oral Candidiasis Recurrent, Radiotherapy; Complications","enrollment":46},{"nctId":"NCT06564116","phase":"PHASE4","title":"Safety and Immunogenicity Study of Thiomersal-free Hepatitis E Vaccine in People Ages 16 Years and Above","status":"COMPLETED","sponsor":"Xiamen Innovax Biotech Co., Ltd","startDate":"2023-03-22","conditions":"Hepatitis E","enrollment":612},{"nctId":"NCT04548518","phase":"PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Elderly","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2020-08-03","conditions":"Influenza","enrollment":816},{"nctId":"NCT04423159","phase":"NA","title":"Immunological Characteristics of a Population at Risk of Cholera After Oral Cholera Vaccine (CHOVAXIM)","status":"COMPLETED","sponsor":"Centre for Infectious Disease Research in Zambia","startDate":"2016-10-16","conditions":"Diarrhea Infectious","enrollment":225},{"nctId":"NCT03391193","phase":"PHASE3","title":"Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-12-19","conditions":"Influenza","enrollment":301},{"nctId":"NCT04522830","phase":"PHASE2","title":"A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19","status":"COMPLETED","sponsor":"Beech Tree Labs, Inc.","startDate":"2020-07-30","conditions":"SARS-CoV-2 Infection","enrollment":28},{"nctId":"NCT02097472","phase":"PHASE1, PHASE2","title":"Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers","status":"COMPLETED","sponsor":"PATH","startDate":"2014-04","conditions":"Pneumonia, Pneumococcal","enrollment":304},{"nctId":"NCT02308540","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants","status":"COMPLETED","sponsor":"PATH","startDate":"2015-01-12","conditions":"Pneumococcal Disease","enrollment":346},{"nctId":"NCT02415842","phase":"","title":"A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-26","conditions":"Immunologic Tests","enrollment":414},{"nctId":"NCT00343915","phase":"PHASE3","title":"Immuno & Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B Vaccine in Subjects Aged 11-15 Yrs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-04-21","conditions":"Hepatitis B","enrollment":267},{"nctId":"NCT02914275","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.","status":"COMPLETED","sponsor":"Seqirus","startDate":"2016-09-27","conditions":"Influenza, Human","enrollment":2250},{"nctId":"NCT00980005","phase":"PHASE3","title":"Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-13","conditions":"Influenza","enrollment":2116},{"nctId":"NCT00778895","phase":"PHASE2","title":"Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-11-10","conditions":"Influenza","enrollment":390},{"nctId":"NCT00764790","phase":"PHASE3","title":"Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-10-01","conditions":"Influenza","enrollment":3317},{"nctId":"NCT01867463","phase":"PHASE1","title":"Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-03-27","conditions":"Malaria","enrollment":230},{"nctId":"NCT00938639","phase":"PHASE2","title":"A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2009-07","conditions":"Influenza Caused by the Novel Influenza A (H1N1) Virus","enrollment":240},{"nctId":"NCT01863433","phase":"PHASE4","title":"A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers","status":"COMPLETED","sponsor":"Seqirus","startDate":"2013-05","conditions":"Influenza, Human","enrollment":120},{"nctId":"NCT00940108","phase":"PHASE2","title":"A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children","status":"COMPLETED","sponsor":"Seqirus","startDate":"2009-08","conditions":"Influenza Caused by the Novel Influenza A (H1N1) Virus","enrollment":370},{"nctId":"NCT01591837","phase":"PHASE4","title":"A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy Volunteers","status":"COMPLETED","sponsor":"Seqirus","startDate":"2012-05","conditions":"Influenza, Human","enrollment":120},{"nctId":"NCT01857297","phase":"PHASE4","title":"A Study to Assess the Immunogenicity and Safety of CSL's 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers","status":"COMPLETED","sponsor":"Seqirus","startDate":"2013-05","conditions":"Influenza, Human","enrollment":120},{"nctId":"NCT00633074","phase":"PHASE2","title":"Non-inferiority Study of GSK Biologicals' Influenza Vaccine GSK576389A Using Different Formulations","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03-03","conditions":"Influenza","enrollment":720},{"nctId":"NCT02545543","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2015-09","conditions":"Influenza, Human","enrollment":2278},{"nctId":"NCT00612768","phase":"PHASE2","title":"Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens:Bioequivalence of PVP Formulations","status":"COMPLETED","sponsor":"Allerderm","startDate":"2008-01","conditions":"Dermatitis, Contact","enrollment":50},{"nctId":"NCT00958126","phase":"PHASE2","title":"A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA","status":"COMPLETED","sponsor":"Seqirus","startDate":"2009-08","conditions":"Influenza","enrollment":1313},{"nctId":"NCT00727428","phase":"PHASE1","title":"Immunogenicity and Safety of GSK Biologicals' FluLaval® TF","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-08-05","conditions":"Influenza","enrollment":110},{"nctId":"NCT02214225","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.","status":"COMPLETED","sponsor":"Seqirus","startDate":"2014-08","conditions":"Influenza, Human","enrollment":3484},{"nctId":"NCT00579345","phase":"PHASE3","title":"Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-10","conditions":"Influenza","enrollment":1522},{"nctId":"NCT00380211","phase":"PHASE3","title":"Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09","conditions":"Influenza","enrollment":660},{"nctId":"NCT00329576","phase":"PHASE4","title":"Evaluate Immune Response Approximately 5 to 6 Years After Receiving Different Formulations of GSK Bio Hep B Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05","conditions":"Hepatitis B","enrollment":632},{"nctId":"NCT00731393","phase":"PHASE3","title":"Immuno & Reacto of TF Trivalent Influenza Split Vaccine 2003/04 or of Std Formulation Influsplit SSW®/Fluarix™ 2003/04","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10","conditions":"Influenza","enrollment":157},{"nctId":"NCT02502331","phase":"PHASE3","title":"Safety and Immunogenicity of a New Formulation of Euvichol®","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2016-03","conditions":"Cholera","enrollment":442},{"nctId":"NCT00973700","phase":"PHASE3","title":"Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-08","conditions":"Novel 2009 Influenza H1N1","enrollment":784},{"nctId":"NCT02212106","phase":"PHASE4","title":"A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years","status":"COMPLETED","sponsor":"Seqirus","startDate":"2014-09","conditions":"Influenza, Human","enrollment":402},{"nctId":"NCT02104869","phase":"PHASE4","title":"Clinical Trial for the Evaluation of Three Regimens of Influenza Vaccination in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2014-04","conditions":"Human Influenza","enrollment":195},{"nctId":"NCT00029185","phase":"NA","title":"Study of Dehydrex in Patients With Corneal Erosion","status":"COMPLETED","sponsor":"Holles Laboratories, Inc.","startDate":"2001-09","conditions":"Corneal Diseases, Recurrence","enrollment":300},{"nctId":"NCT01173211","phase":"PHASE2","title":"2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-09","conditions":"Influenza","enrollment":183},{"nctId":"NCT00133549","phase":"PHASE2","title":"9-valent CRM 197 Pneumococcal","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2000-11","conditions":"Pneumococcal Infection","enrollment":180},{"nctId":"NCT01349283","phase":"PHASE3","title":"Immunogenicity and Safety of the Hepatitis B Vaccine Hepavax-Gene TF and a Comparator Hepatitis B Vaccine in Newborns","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2011-05","conditions":"Hepatitis B","enrollment":1738},{"nctId":"NCT01986335","phase":"PHASE3","title":"Protectivity and Safety of DTP/HB/Hib (Bio Farma) Vaccines in Infants, Batch Consistency, Multi Center Trial","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2012-08","conditions":"Healthy","enrollment":600},{"nctId":"NCT01986322","phase":"PHASE2","title":"Immunogenicity and Safety of DTP/HB/Hib (Bio Farma)Compared to DTP/HB Given Simultaneously With Hib(Registered)Vaccine","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2011-07","conditions":"Healthy","enrollment":220},{"nctId":"NCT01977196","phase":"PHASE1","title":"The Safety and Immunogenicity of DTP/Hepatitis B 10ug Hib Vaccine (Bio Farma)","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2011-04","conditions":"Healthy","enrollment":30},{"nctId":"NCT00912496","phase":"PHASE1","title":"Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-06","conditions":"Influenza","enrollment":637},{"nctId":"NCT00342628","phase":"PHASE2","title":"Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2006-07","conditions":"Typhoid Fever","enrollment":301},{"nctId":"NCT00905125","phase":"PHASE2","title":"Influenza Vaccine in Pregnant Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-06","conditions":"Influenza","enrollment":102},{"nctId":"NCT00138333","phase":"","title":"Mercury Levels in Premature and LBW Infants Receiving Thimerosal-containing Vaccines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-12","conditions":"Mercury Levels","enrollment":71},{"nctId":"NCT00333398","phase":"PHASE3","title":"Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-06","conditions":"Influenza","enrollment":1359},{"nctId":"NCT00731029","phase":"PHASE3","title":"Reacto & Immunogenicity of TF Formulation of Influsplit SSW® 2002/03 v/s Std Formulation of Influsplit SSW® 2002/03","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-09","conditions":"Influenza","enrollment":239}],"_emaApprovals":[],"_faersSignals":[],"administration":{"route":"Oral"},"crossReferences":{"chemblId":"CHEMBL508338"},"_approvalHistory":[],"publicationCount":1358,"recentPublications":[{"date":"2026 Mar","pmid":"41806302","title":"TMEM16A Contributes to Calcium-Activated Chloride Currents and Membrane Potential Changes in the Mouse Oocyte.","journal":"Journal of cellular physiology"},{"date":"2026 Jan 27","pmid":"41683680","title":"Chilling Does Not Affect the Functionality of Intracellular Calcium Stores in Viable Boar Sperm During Liquid Preservation.","journal":"International journal of molecular sciences"},{"date":"2026 Feb 6","pmid":"41649155","title":"Letter: Decline in Thimerosal Patch Test Positivity Following Removal from Vaccinations.","journal":"Dermatitis : contact, atopic, occupational, drug"},{"date":"2026","pmid":"41613797","title":"Thimerosal Inhibits Tumor Malignant Progression through Direct Action and Enhancing the Efficacy of PD-1-Based Immunotherapy.","journal":"Oncology research"},{"date":"2026 Jan 28","pmid":"41593398","title":"Preparation and Serological Evaluation of an Inactivated Trivalent Oil Emulsion Vaccine for Avian Fowl Adenovirus (FAdV) Containing - 8a, 8b, and 11 Serotypes.","journal":"Current microbiology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"THIMEROSAL","genericName":"THIMEROSAL","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:36:58.460835+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}